[1] Lee LS,Kinzig-Schippers M,Nafziger AN,et al.Comparison of 30min and 3h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation [J].Diagn Microbiol Infect Dis,2010,68(3):251-258.
[2] Peric M,Browne FA,Jacobs MR,et al.Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections:Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents[J].Clin Ther,2003,25(1):169-177.
[3] 李小芳,宋香清.哌拉西林他唑巴坦抗铜绿假单胞菌感染的T>MIC%的推导及在方案评价与优化中的作用[J].中国药师,2015,18(7):1086-1091.
[4] 宋香清,龙明辉,杨立平.基于T>MIC简易数学模型的哌拉西林他唑巴坦给药方案设计与优化[J].中国医院药学杂志,2016,36(11):911-916.
[5] 宋香清,龙明辉,杨立平,等.颅脑外科手术患者术中预防使用抗菌药物追加时机与次数研究[J].中华医院感染学杂志,2016,26(18):4151-4154.
[6] Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing:Twenty-second Informational Supplement M100-S26[S].USA,2016:52-112.
[7] 杨 阳,李 昕,王 林,等.基于PK/PD参数的碳青霉烯类药物给药方案设计[J].中南药学,2013,11(2):157-159.
[8] Iakovlev SV,Beloborodov VB,Sidorenko SV,et al.Multi-centre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections:Results of clinical and pharmacoeconomic analysis[J].Antibiot Chemother,2006,51(7):15-27.
[9] Koomanachai P,Bulik CC,Kuti JL,et al.Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[J].Clin Ther,2010,32(4):766-779.
[10] Li C,Du X,Kuti JL,et al.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections[J].Antimicrob Agents Chemother,2007,51(5):1725-1730.
[11] McKinnon PS,Paladino JA,Schentag JJ.Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections[J].Int J Antimicrob Agents,2008,31(4):345-351.
[12] Zhou QT,He B,Zhang C,et al.Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections:Population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study[J].Drugs Aging,2011,28(11):903-912.
[13] Fraenkel CJ,UllbergM,Bernander S,et al.In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals[J].Scand J Infect Dis,2006,38(10):853-859.